Global Cardiac Arrest Treatment Market Size (2024 - 2029)

The cardiac arrest treatment market is anticipated to experience growth over the forecast period, driven by the increasing prevalence of cardiac diseases and a rising geriatric population. The market size is influenced by the availability of technologically advanced products and supportive reimbursement policies. Although the COVID-19 pandemic negatively impacted the market by reducing the demand for cardiac devices and drugs due to canceled procedures, the market has begun to recover with the resumption of these services. However, challenges such as inadequate healthcare infrastructure, a shortage of skilled professionals, and the high cost of treatments may hinder market expansion.

Market Size of Global Cardiac Arrest Treatment Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Cardiac Arrest Treatment Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 4.80 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Cardiac Arrest Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Cardiac Arrest Treatment Market Analysis

The cardiac arrest treatment market is expected to register a CAGR of 4.8% over the forecast period.

The outbreak of the pandemic impacted the market. The cancelation of cardiac procedures during COVID-19 adversely impacted the market as it decreased the demand for devices and drugs used in cardiac arrest cases. For instance, according to an NCBI research study published in May 2021, during the COVID-19 pandemic, cardiac procedural activity in England decreased dramatically, with a deficit of about 45,000 procedures, with no increase in the risk of mortality for most cardiac procedures conducted during the pandemic. The same source also stated the negative impact of COVID-19 on cardiology services. Furthermore, according to a PLOS research study published in October 2021, during the pandemic, there was a dramatic drop in referrals and procedures completed for cardiac operations.

Additionally, a European Heart Journal Supplements article published in December 2021 reported that many left atrial appendage occlusion procedures were canceled during the pandemic. However, with the resumption of cardiac procedures amidst declining cases of COVID-19, the market started to gain momentum and is expected to maintain an upward trend over the forecast period.

The increasing prevalence of cardiac diseases and rising geriatric population and the availability of technologically advanced products and reimbursement policies are the major drivers for the market. For instance, according to a research study published in January 2021, the most common cardiac arrhythmia is atrial fibrillation, which is a major risk factor for ischemic stroke and causes an enormous economic burden as well as morbidity and mortality. Furthermore, as per the same source, it is estimated that atrial fibrillation will affect 6 to 12 million people in the United States by 2050, while it will affect 17.9 million people by 2060. This data shows a significant prevalence of atrial fibrillation. Similarly, according to data published by the British Heart Foundation in August 2022, in the United Kingdom, over 7.6 million people lived with heart or circulatory disease in 2021. According to an NCBI research study published in August 2022, cardiovascular diseases were highly prevalent in the rural areas of South Asia, with an incidence of 5.41 per 1,000 person-years as compared to 4.73 per 1,000 person-years in urban areas, and the incidence was higher among males. 

The increasing geriatric population across the globe is also anticipated to propel market growth as older people are more prone to cardiac diseases. For instance, according to the World Population Aging Highlight 2021 report published by the United Nations, the global geriatric population is increasing rapidly around the world, and in 2021, more than 727.0 million people aged 65 years or more were living across the world, which was about 9.3% of the total global population. The same report projected that the population of people aged 65 years or more will be about 1.5 billion people by 2050, which will be about 16.0% of the global population. 

While several factors point to the growth of the market, the lack of advanced healthcare infrastructure, skilled professionals, and highly expensive treatments may restrain the market growth over the forecast period.

Cardiac Arrest Treatment Industry Segmentation

As per the scope of the report, cardiac arrest is an emergency when the heart fails to pump blood effectively and stops beating, when there is a loss of consciousness, and abnormal or absence of breathing in severe cases. The cardiac arrest treatment market is segmented by Treatment (Drugs (Vasopressors, Anti-arrhythmic Drugs, Anticholinergic Drugs, Antihypertensives, and Other Drugs) and Medical Devices (Cardiac Resynchronization Therapy (CRT), Defibrillators, Other Medical Devices)), Distribution Channels (Hospitals, Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment
Drugs
Vasopressors
Anti-arrhythmic Drugs
Anticholinergic Drugs
Antihypertensives
Other Drugs
Medical Devices
Cardiac Resynchronization Therapy (CRT)
Defibrillators
Other Medical Devices
By Distribution Channel
Hospitals
Pharmacies
Other Distribution Channels
Geography
North America
United states
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Cardiac Arrest Treatment Market Size Summary

The cardiac arrest treatment market is poised for steady growth, driven by the increasing prevalence of cardiovascular diseases and a rising geriatric population. The market experienced a temporary setback due to the COVID-19 pandemic, which led to a significant reduction in cardiac procedures and a subsequent decline in demand for related devices and drugs. However, as healthcare services resumed and the demand for cardiac procedures rebounded, the market began to regain momentum. Technological advancements in treatment products and supportive reimbursement policies are further propelling market expansion. Despite these positive trends, challenges such as inadequate healthcare infrastructure and the high cost of treatments may hinder market growth.

North America is expected to be a significant contributor to the market's expansion, fueled by the high incidence of cardiovascular diseases and substantial investments in research and development. The region's aging population, particularly in the United States, is anticipated to drive demand for cardiac arrest treatments. Key players in the market are actively launching innovative products and forming strategic partnerships to enhance their competitive edge. The market is characterized by moderate competition, with major companies like Koninklijke Philips NV, Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, and Novartis AG leading the way. These developments, along with ongoing product approvals and collaborations, are expected to sustain the market's growth trajectory over the forecast period.

Explore More

Global Cardiac Arrest Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence Of Cardiac Diseases And Rising Geriatric Population

      2. 1.2.2 Availability of Technologically Advanced Products and Reimbursement Policies

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Advanced Healthcare Infrastructure, Skilled Professionals, and Highly Expensive Treatments

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Buyers/Consumers

      2. 1.4.2 Bargaining Power of Suppliers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Treatment

      1. 2.1.1 Drugs

        1. 2.1.1.1 Vasopressors

        2. 2.1.1.2 Anti-arrhythmic Drugs

        3. 2.1.1.3 Anticholinergic Drugs

        4. 2.1.1.4 Antihypertensives

        5. 2.1.1.5 Other Drugs

      2. 2.1.2 Medical Devices

        1. 2.1.2.1 Cardiac Resynchronization Therapy (CRT)

        2. 2.1.2.2 Defibrillators

        3. 2.1.2.3 Other Medical Devices

    2. 2.2 By Distribution Channel

      1. 2.2.1 Hospitals

      2. 2.2.2 Pharmacies

      3. 2.2.3 Other Distribution Channels

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United states

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Cardiac Arrest Treatment Market Size FAQs

The Global Cardiac Arrest Treatment Market is projected to register a CAGR of 4.80% during the forecast period (2024-2029)

Koninklijke Philips N.V, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation and Novartis AG are the major companies operating in the Global Cardiac Arrest Treatment Market.

Cardiac Arrest Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)